Sirona Biochem (
TSX: V.SBM,
Stock Forum) advanced its developmental efforts with its glycoprotein SBM-TCF-837 when the company announced today that its French partner, Biogalenys, observed positive effects of SBM-TCF-837 on human fibroblasts in preliminary, in vitro, studies in response to the stressed condition of ultraviolet (UV) radiation.
According to the
news release, these studies showed a significant increase in percent cell viability over time with SBM-TCF-837, pointing to the possibility that glycoprotein plays an integral part in protection against UV induced cell death.
More studies are scheduled as the aforementioned compounds could be used in such things as anti-aging cosmetic products; cryopreservation; regenerative and protective cosmetic products for healing, wound care, hypothermic protection, etc; preservation of stem cells and preservatives for vaccines.
The company seeks to capture a slice of the global anti-aging market which is expected to hit $345.8 billion in 2018 as well as a piece of the regenerative medicine market anticipated to reach US$67.6 billion in 2020.
Company Chief Business Development Officer, Attila Hajdu, commented on the news, “These results are tremendously exciting and further add to our previously reported results which demonstrated that our glycoproteins were protective against extreme conditions.”
Then he concluded, “We have added this new data to our existing patent and have recently generated significant interest from major pharmaceutical companies that recognize the value that our fluorination platform technology provides.”
Sirona Biochem was in the news recently when
the Vancouver-based company announced almost two weeks ago that it would present at BIO Asia 2015.
Shares climbed 10.00% on the news to $0.165 per share.
Currently there are 138.9m outstanding shares with a market cap of $22.9 million.